Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. University of Sydney at Westmead Hospital, Sydney, Australia



Survival: 10.6 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: Australia
   
City/State/Province: Sydney
   
Hospital: University of Sydney at Westmead Hospital
   
Journal: Link
   
Date: 3/2010

Description:
Patients:
This study involved patients with metastatic melanoma who had not received prior chemotherapy. Patients were separated into two separate treatment groups. Group A had 40 patients with a median age of 58 years and 55% male. Group B also had 40 patients, with a median age of 62.1 years and 70% male.

Treatment:
Patients in group A were treated with the chemotherapy agent dacarbazine and a placebo (i.e. sugar pill). Group B was given the chemotherapy agent dacarbazine and the biologic therapy agent bosentan, which inhibits a protein (endothelin receptor) to stop cancer cell growth.

Toxicities:
The maximum toxicity grade reported for both groups was grade 4. Group A included 1 case of grade 4 neutropenia and 3 cases of grade 3 dyspnea (shortness of breath). Group B had 1 case of grade 4 anemia, 1 case of grade 4 thrombocytopenia, and 5 cases of grade 3 neutropenia. Overall, the most common adverse effects were nausea and fatique.

Results:
The median progression-free survival for group A was 2.8 months and the median overall survival was 10.6 months. For group B, the median progression-free survival was 1.6 months and the median overall survival was 13.0 months.

Support:
This study was supported by Actelion Phamaceuticals, Ltd., the makers of bosentan (brand name Tracleer).

Correspondence: Dr. Richard F Kefford; email: rick_kefford@wmi.usyd.edu.au

E-mail to a Friend Email Physician More Information